Susan Swetter, M.D.
Clinical Trials
- Recruiting A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
- Recruiting Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
- Recruiting Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
- Not Recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
- Recruiting Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
- Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
- Not Recruiting Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
- Not Recruiting A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
- Not Recruiting Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
- Not Recruiting Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
- Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Help